Compare GRMN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRMN | INSM |
|---|---|---|
| Founded | 1990 | 1988 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5B | 41.2B |
| IPO Year | 2000 | 2000 |
| Metric | GRMN | INSM |
|---|---|---|
| Price | $195.41 | $207.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $239.50 | $173.35 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | ★ 3.11 | N/A |
| EPS | ★ 8.11 | N/A |
| Revenue | ★ $6,943,125,000.00 | $447,022,000.00 |
| Revenue This Year | $15.45 | $40.09 |
| Revenue Next Year | $6.78 | $129.64 |
| P/E Ratio | $24.09 | ★ N/A |
| Revenue Growth | 16.56 | ★ 30.34 |
| 52 Week Low | $169.26 | $60.40 |
| 52 Week High | $261.69 | $209.77 |
| Indicator | GRMN | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.28 | 70.03 |
| Support Level | $186.67 | $202.27 |
| Resistance Level | $194.27 | $209.77 |
| Average True Range (ATR) | 3.97 | 6.68 |
| MACD | 1.51 | -0.06 |
| Stochastic Oscillator | 50.07 | 89.91 |
Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.